Stay updated on Nivolumab in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab in Hodgkin Lymphoma Clinical Trial page
- Check5 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. This appears to be a minor metadata update with no impact on study content or functionality.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2. Deleted: the government funding lapse notice and the earlier Revision: v3.4.1; these are administrative changes and do not affect the study content, eligibility criteria, or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check41 days agoChange DetectedA funding/operational status notice was added, and the site revision tag updated to v3.4.1, replacing the previous v3.4.0 tag.SummaryDifference0.3%

- Check48 days agoChange DetectedUI changes include showing the glossary and adding a QC metadata line (Last Update Submitted that Met QC Criteria). The revision number was updated to v3.4.0 and No FEAR Act Data labeling was adjusted.SummaryDifference0.2%

- Check62 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4. The study details and layout remain unchanged.SummaryDifference0.0%

- Check83 days agoChange DetectedAn administrative change was made: a new Revision: v3.3.3 was added and the HHS Vulnerability Disclosure and Revision: v3.3.2 were removed from the page footer. The study content, eligibility criteria, and outcomes remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Hodgkin Lymphoma Clinical Trial page.